GRCL(Delisted)
Gracell·NASDAQ
--
--(--)
GRCL Profile
Gracell Biotechnologies Inc.
A Chinese clinical-stage biopharmaceutical company that develops cell therapies for the treatment of cancer
--
05/22/2018
01/08/2021
NASDAQ Stock Exchange
314
12-31
Depository Receipts (Ordinary Shares)
Building 12, Block B, Phase II, Biobay Industrial Park, 218 Sangtian St., Suzhou Industrial Park, 215123, People’s Republic of China
Development of cell-based therapies for cancer
Genxi Biotechnology, an exempted limited liability company incorporated in the Cayman Islands on May 22, 2018, is a global clinical-stage biopharmaceutical company dedicated to the discovery and development of breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Genxi Bio is developing a rich pipeline of autologous and allogeneic clinical-stage cancer treatment products. These products are expected to overcome the persistent major industry challenges of traditional CAR-T therapies, including long production time, poor product cell quality, high treatment cost and lack of effective treatment for solid tumors.
